0001191638-16-002184.txt : 20160603 0001191638-16-002184.hdr.sgml : 20160603 20160603064601 ACCESSION NUMBER: 0001191638-16-002184 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160603 FILED AS OF DATE: 20160603 DATE AS OF CHANGE: 20160603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 161694177 BUSINESS ADDRESS: STREET 1: 2 KINGDOM STREET - LEGAL DEPARTMENT CITY: LONDON STATE: X0 ZIP: W2 6BD BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 2 KINGDOM STREET - LEGAL DEPARTMENT CITY: LONDON STATE: X0 ZIP: W2 6BD FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 azn201606036k.htm AZ COMPLETES US LICENSING AGREEMENT WITH IRONWOOD azn201606036k.htm
 

FORM 6-K


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of June 2016

Commission File Number:  001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X            Form 40-F  __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  __                 No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________
 
 
 
 
ASTRAZENECA COMPLETES US LICENSING AGREEMENT WITH IRONWOOD PHARMACEUTICALS FOR LESINURAD
 
AstraZeneca today announced that it has completed the licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol. Zurampic is approved in the US, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with uncontrolled gout. The fixed-dose combination will be submitted for regulatory review in the second half of 2016.
 
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
 
 
CONTACTS
 
Media Enquiries
 
    
Neil Burrows
 
UK/Global
+44 7824 350541
Vanessa Rhodes
 
UK/Global
+44 7880 400690
Karen Birmingham
 
UK/Global
+44 7818 524012
Jacob Lund
 
Sweden
+46 8 553 260 20
Michele Meixell
 
US
+1 302 885 2677
Investor Enquiries
 
    
UK
    
Thomas Kudsk Larsen
 
  
+44 7818 524185
Nick Stone
 
RIA
+44 7717 618834
Henry Wheeler
Oncology
+44 7788 354619
 
Craig Marks
Finance
 
+44 7881 615764
Christer Gruvris
 
ING
+44 7827 836825
US
    
Lindsey Trickett
 
CVMD
+1 240 543 7970
Mitchell Chan
 
Oncology
+1 240 477 3771
Dial / Toll-Free
 
  
+1 866 381 7277
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal
 
 
3 June 2016
 
-ENDS-
 
 
 SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
AstraZeneca PLC

 
Date: 03 June 2016
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary